Nicholas Brownstone
Dermatology · New York, NYNPI 1740643980
Payments from drug & device makers
Across 247 payments — averaging $60.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Mindera Corp$2K
- AbbVie$2K
- LEO Pharma Inc.$2K
- UCB, Inc.$917
- Dermavant Sciences, Inc.$713
- plus $5K from 18 others
What the payments were for
- Consulting fees$2,00013%
- Food & beverage$12,04481%
- Education$8165%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 58 | $2,438 |
| Mindera Corp | 1 | $2,000 |
| AbbVie | 61 | $1,897 |
| LEO Pharma Inc. | 31 | $1,743 |
| UCB, Inc. | 17 | $917 |
| Dermavant Sciences, Inc. | 6 | $713 |
| Sun Pharmaceutical Industries Inc. | 7 | $675 |
| Boehringer Ingelheim | 5 | $657 |
| Regeneron Healthcare Solutions, Inc. | 7 | $593 |
| Pfizer | 7 | $521 |
| Sanofi | 8 | $476 |
| Arcutis Biotherapeutics, Inc. | 5 | $449 |
| Galderma Laboratories, L.p. | 10 | $334 |
| Verrica Pharmaceuticals Inc. | 4 | $283 |
| Lilly USA, LLC | 4 | $242 |
| Janssen Scientific Affairs, LLC | 2 | $220 |
| Incyte Corporation | 5 | $178 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $151 |
| E.r. Squibb & Sons, L.L.C. | 1 | $133 |
| Cipher Pharmaceuticals US LLC | 1 | $108 |
| Amryt Pharma Holdings Ltd | 1 | $49 |
| Blueprint Medicines Corporation | 1 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Botanix SB Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,860 in reported general payments places this provider in the 80th percentile of 1,151 dermatology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 119 | $422,824 |
| TremfyaGuselkumab | 24 | $315,167 |
| Skyrizi PenRisankizumab-Rzaa | 11 | $225,600 |
| Humira(Cf) PenAdalimumab | 22 | $174,040 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $150,702 |
| RinvoqUpadacitinib | 16 | $100,494 |
| AdbryTralokinumab-Ldrm | 21 | $78,140 |
| XolairOmalizumab | 25 | $65,760 |
| Tacrolimus | 68 | $13,787 |
| Clobetasol Propionate | 154 | $11,810 |
| Clindamycin Phosphate | 44 | $1,578 |
| Doxycycline Monohydrate | 37 | $904 |
| Permethrin | 14 | $656 |
| Ketoconazole | 44 | $631 |
| Triamcinolone Acetonide | 60 | $624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $2,438 | $315,16724 claims |
| AbbVieRinvoq | $1,897 | $100,49416 claims |
| LEO Pharma Inc.Adbry | $1,743 | $78,14021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,151 dermatology providers in New York.
Other dermatology in New York
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
- Andrew AlexisNew York$5.7M
- Neil SadickNew York$4.2M
- Orit MarkowitzNew York$3.7M
- Alexandra GolantNew York$3.6M
- George HanNew York$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.